Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioAlliance Pharma unveils €16M rights issue

This article was originally published in Scrip

Executive Summary

BioAlliance Pharma, the Paris-based specialty and orphan oncology company, is intending to raise €16 million through the issue of 3,395,943 shares at €4.90 each. The capital raised will be used to continue development of Livitag (Doxorubicin Transdrug) to treat primary liver cancer, secure additional orphan assets, and longer term consider strategic commercialisation options in some territories. Holders of existing shares will be able to buy one share for every four they already own.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC013543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel